Contact Information

Mark Zervas, Ph.D.
Email: mzervas@zervsciconsult.com

LinkedIn: http://linkedin.com/in/markzervas

Mark Zervas, Ph.D. is an experienced Life Sciences leader with background in the following three sectors:
1. Nonprofit (Head of Discovery and Preclinical Science at Cohen Veterans Bioscience)
2. Industry (Senior Scientist at both Amgen and Alnylam)
3. Academia (Manning Assistant Professor of Biology)

As Head of Discovery and Preclinical Research Dr. Zervas led the initiaitve to identify and prioritize therapeutic targets for PTSD. This resulted in a 2025 publication in Frontiers in Drug Discovery, which described the strategy as well as 20 putative PTSD targets. In addition, he developed a novel discovery platform that integrated human iPSC-derived neural cituits, blood brain barrier cells, astrocytes, microglia (biological components), and a presure blast mechanism to interrogate blast-releated traumatic brain injury mechanisms and theraeutics designed to repair the Blood Brain Barrier.

As Senior Scientist, Dr. Zervas developed in vitro assays using human induced pluripotent stem cells and approaches to tackle human genetic based targets supporting Parkinson's Disease Research and managed teams conducting in vivo assays to validate molecules designed to ameliorate chronic neuropathic pain as well as ocular disorders.

During his time in academia, Dr. Zervas designed novel mouse genetic models, which were used for studying neurodevelopmental disorders and understanding developmental neurobiology. He also conducted in vivo and in vitro assays supporting discovery efforts, which led to first approved therapy (Miglustat) for Niemann-Pick Disease Type C (NPC). More recently, Miglustat is used an adjunct therapeutic molecule supporting the first FDA approved therapy for NPC (MIPLYFFA).